Kornimate/medical-research-clean huggingface dataset:
hypoglycemia and autonomic nervous system function-b

Conditions: Hypoglycemia; Healthy

Summary: this study tests the hypothesis that, compared to prior normal blood sugar, prior low blood sugar impairs cardiovascular autonomic function. the proposed studies will also test the hypothesis that the effects of prior low blood sugar on cardiovascular autonomic function are blocked by administration of a mineralocorticoid receptor antagonist.

this study involves three interventions, which are performed in random order. each intervention involves a 3-day inpatient visit. there is a space of 1-3 months between interventions. the three interventions are: 1) placebo with a hyperinsulinemic euglycemic clamp, 2) spironolactone with a hyperinsulinemic hypoglycemic clamp, or 3) placebo with a hyperinsulinemic hypoglycemic clamp. each 3-day inpatient visit includes the following. on day 1, autonomic testing is performed. autonomic testing includes assessment of baroreflex sensitivity (brs). brs is assessed using the modified oxford procedure, which involves sequential administration of nitroprusside and phenylephrine while measuring heart rate and beat to beat blood pressure with a finapress and assessing muscle sympathetic nerve activity (msna). msna is measured using microelectrodes placed near the peroneal nerve. on day 2, hyperinsulinemic clamps are performed with pre-treatment with either placebo or spironolactone. modified oxford procedures are performed prior to and during each clamp on day 2. on day 3, the autonomic testing performed on day 1 is repeated..

Eligibility criteria:
inclusion criteria: * healthy volunteers * males and females age 18 to 55 years exclusion criteria: * pregnancy * lactation * clinically evident coronary artery, cerebrovascular, or peripheral vascular disease, or presence of systemic illness that might affect autonomic function. such illnesses include diabetes mellitus, congestive heart failure, hypertension, renal, pulmonary, hepatic disease, anemia, malignancies, untreated thyroid disease, and alcoholism. * current major depressive illness * in all subjects, any individuals on oral, injected, inhaled or topical corticosteroids within the last year or oral contraceptives within the past 3 months will be excluded. * use of medications other than thyroxine * known hypersensitivity to nitroglycerin, nitroprusside and/or phenylephrine. * blood pressure \> 140/90 mmhg * creatinine \> 1.5 mg/dl * serum potassium \>5.2 mmol/l * estimated gfr \< 50 ml/min * use of viagra, cialis, and similar drugs within 72 hours of admission.
oncorine (h101) combined with tislelizumab and chemotherapy in previously untreated advanced non-small cell lung cancer

Conditions: Untreated Advanced Non-small Cell Lung Cancer

Summary: this is a single-arm, single-centre phase ii study to evaluate the efficacy (pfs, orr, dcr) and safety of recombinant human adenovirus type 5 in combination with tirelizumab and platinum-containing dual-agent chemotherapy in previously untreated patients with advanced non-small cell lung cancer who are egfr/alk negative. the study is divided into 2 phases.

phase 1 is a preliminary exploration of safety and efficacy. the safety and efficacy of the regimen was assessed in the 10 patients enrolled for interim analysis. phase 2 will continue to expand the sample size to assess the efficacy and safety of the regimen, with 20 patients planned to be enrolled.

Eligibility criteria:
inclusion criteria: 1. fully informed about the study and voluntarily signed an informed consent form (icf); ≥18 years and ≤75 years; 2. ecog score 0-1; 3. non-small cell lung cancer (nsclc) confirmed by histology or pathology; 4. stage iv on imaging assessment; 5. no egfr or alk gene mutations (genetic testing may not be performed in patients with squamous lung cancer); 6. no previous antitumour treatment for nsclc no prior antitumour therapy for nsclc; 7. lesions suitable for intratumour injection of drugs; 8. measurable or assessable lesions according to recist 1.1 criteria. exclusion criteria: 1. histological or cytological pathology of the tumour confirms a combined small cell lung cancer component; 2. those with tests suggesting severe organ dysfunction; 3. subjects with any active, known or suspected autoimmune disease are excluded; 4. expected survival is less than 3 months.
revascularization effect on csvd burden in carotid artery stenosis

Conditions: Carotid Artery Stenosis; Cerebral Small Vessel Diseases

Summary: recas is a prospective cohort of 1,000 patients with carotid artery stenosis (cas) and undergoing revascularization therapy or standard medication treatment alone. the goal of this study is to validate whether cas revascularization when compared to standard medication treatment alone, can effectively reduce the progression of cerebral small vessel disease (csvd) burden, as well as improve the severity of retinal pathologies and cognitive impairment. therefore, patients aged ≥ 40 years have more than 50% stenosis in unilateral carotid artery and sign informed consent will be recruited. in this study, patients will be asked to undergo computed tomography angiography (cta)/ digital subtraction angiography (dsa), computed tomography perfusion (ctp),multimodal magnetic resonance imaging (mri), optical coherence tomography angiography (octa) and neuropsychological testing. estimated follow-up can be up to 10 years.


Eligibility criteria:
inclusion criteria: 1. patients aged ≥ 40 years. 2. ≥ 50% stenosis in unilateral carotid artery. 3. sign informed consent. exclusion criteria: 1. previous history of major head trauma and any intracranial surgery 2. intracranial abnormalities, such as intracerebral hemorrhage, subarachnoid hemorrhage, and other space occupying lesions 3. extrapyramidal symptoms or mental illness which may affect neuropsychological measurement. 4. severe loss of vision, hearing, or communicative ability.

Keywords: carotid artery stenosis cerebral small vessel diseases revascularization carotid artery stenting prospective cohort
safety and efficacy of inhaled synthetic thc/cbd for improving physical functioning and for modulating cachexia progression in patients with advanced cancer and associated cachexia

Conditions: Cannabis Use; Cachexia; Cancer; Advanced Cancer

Summary: a large number of patients with advanced cancer also suffer from cachexia. cachexia is a syndrome characterized by loss of skeletal muscle mass (with/or without loss of fat mass) that cannot be reversed by nutritional support and progressively leads to functional impairment. patients who suffer from anorexia and cachexia have lower survival rates. some patients with cancer use cannabis to improve the way they feel and relieve their pain. however, there is very sparse high-quality research to prove that cannabis products are truly effective. this study will investigate patients with advanced cancer who use inhaled therapeutic cannabinoid-based medication (ppp011), in addition to palliative care management, and will assess if these patients experience improvement in functional status as a surrogate endpoint for survivalquality

this is a 12-week randomized, double-blind, placebo-controlled, parallel group design trial to evaluate the safety and efficacy of inhaled ppp011 on physical functioning and cachexia progression in patients with cachexia related to advanced incurable cancer.

Eligibility criteria:
inclusion criteria: 1. written informed consent, 2. adult male and female patients at least 18 years of age, 3. patient agreed to follow the protocol, 4. advanced cancer for which there is no known curative therapy, 5. the patient has a cachexia weight loss of grade of 2 or grade 3 cachexia as follow (based on weight loss grading system) weight loss accounts for the last 6 months before screening. 6. patient's weight 6 months before screening must be available 7. karnofsky performance status score ≥ 60 % 8. life expectancy of at least 4 months, excluding refractory cachexia 9. no cognitive impairment according to mini-cog negative confusion assessment according to cam, 10. the patient is able to perform deep inhalations with fev1 more than 60%, 11. ability to read and respond to questions in french or english or french or spanish, 12. a female volunteer must meet one of the following criteria: if of childbearing potential - agrees to use one of the accepted contraceptive regimens from at least 28 days prior to the first drug administration, during the study and for at least 60 days after the last dose, if of non-childbearing potential - should be surgically sterile or in a menopausal state, a male volunteer with sexual partners who are pregnant, possibly pregnant, or who could become pregnant must be surgically sterile or agrees to use one of the accepted contraceptive regimens from first drug administration until 3 months after the last drug administration.
exploration of genotype based personalized prescription of cyclophosphamide in systemic lupus erythematosus treatment

Conditions: Lupus Erythematosus, Systemic; Adverse Effects

Summary: the purpose of this study is to investigate the relationship between the side effects of cyclophosphamide in the treatment of systemic lupus erythematosus (sle) in han chinese and the genetic polymorphisms of drug metabolizing enzymes and pharmacokinetics of cyclophosphamide.

cyclophosphamide is a widely applied agent in treatment of systemic lupus erythematosus. as an alkylating agent, cyclophosphamide is able to induce several side effects, including thinned hair, loss of appetite, nausea, vomiting, infection, myelosuppression, etc. however, the remarkable variability of the reactions to the drug -- the incidence of side effect or the outcome of the treatment -- has been observed among patients. cyclophosphamide is a pro-drug, which require some enzymes in the liver to transform it into an active chemical to arouse alkylating function. and then it undergoes a series of detoxification steps catalyzed by the specific metabolic enzymes. this study is designed to explore the genetic variation among individuals in the key processes of the activation and elimination of cyclophosphamide in order to find out whether these genetic factors are associated to the side effects or efficacy. the further understanding into the factors concerning on the drug might imply possible solution to minimize the incidence of side effects in patients of systemic lupus erythematosus.

Eligibility criteria:
inclusion criteria: 1. the patients must have been diagnosed as sle according to the american college of rheumatology (acr) criteria published in 1997. 2. the patients must sign the informed consent. and for the patients who are under 18 years old, both the signatures of their legal guardians and that of the patients are required on the written informed consent. 3. the patients are receiving the standard regimen of 0.2g cyclophosphamide given as intravenous injection once every two days. exclusion criteria: 1. pregnant women, women in breast-feeding period and the women who refuse to take contraception measures during treatment. 2. patients with poor compliance. 3. patients who are also diagnosed of cancer or who are receiving cyclophosphamide in treatment of cancer, or other anti-cancer therapy.

Keywords: myelosuppression infection nausea
efficacy and safety study of advantan for maintenance treatment of atopic dermatitis

Conditions: Dermatitis, Atopic

Summary: purpose of the study: one bothering feature of atopic dermatitis is its relapsing nature. hence, it is worthwhile to test modes how to efficiently prevent relapses or at least increase the time until the disease recurs. in order to give recommendations to other patients, this study is to scientifically describe efficacy and safety of a given regimen, namely a maintenance therapy with two days a week advantan.

the study has initially been posted by schering ag, germany. schering ag, germany has been renamed to bayer schering pharma ag, germany. intendis gmbh, a bayer healthcare company, is the sponsor of the trial.

Eligibility criteria:
inclusion criteria: * acute 'severe' or 'very severe' flare of atopic dermatitis; no minimum affected body surface * history of moderate to severe form of atopic dermatitis for at least two years exclusion criteria: * pregnancy, breast feeding * known immune, hepatic, or renal insufficiency * acute herpes simplex or mollusca contagiosa infection * acute and severe impetigo contagiosa. a slight superinfection of eczema is no exclusion criterion * severe other viral, bacterial, or fungal skin infection (chicken pox, prominent tinea corporis) * acute infestations (e.g. head lice, scabies)
covid-19 vaccinations with a sweepstakes

Conditions: Covid19

Summary: to reach herd immunity for covid-19, experts estimate that 70% of the population will need to be vaccinated. however, vaccination rates have begun to slow down in the united states. the investigators will partner with philadelphia to launch a covid-19 vaccination sweepstakes, in which residents will be eligible to win if they have received at least one dose of the covid-19 vaccine prior to a given drawing. drawings will be held every two weeks; multiple prizes of various sizes will be awarded in each drawing. half of the prizes in each size category in each drawing will be awarded to residents of a zip code that is randomly selected from a pre-defined list of under-vaccinated zip codes (this zip code will be announced at the start of each 2-week drawing period), the other half will be awarded to residents outside of that selected zip code. the investigators will analyze vaccination rates in philadelphia as compared with neighboring regions before, during, and after the specified time period, as well as analyze vaccination rates in the three selected zip codes compared to the other zip codes that could have been targeted (the residual set of under-vaccinated zip codes) to determine the effectiveness of the sweepstakes at encouraging vaccinations.


Eligibility criteria:
inclusion criteria: * all 18+ residents of the city of philadelphia will be eligible. residents will be able to win the sweepstakes prizes if they can verify they received at least one dose of the covid-19 vaccine before the date of the sweepstakes drawing in question. exclusion criteria: * none.

Keywords: covid19 vaccination behavioral science interventions vaccination promotion
study to evaluate the safety and efficacy of dietary supplement anatabloc in reducing daily smokers' urge to smoke

Conditions: Tobacco Use Disorder; Tobacco Dependence; Smoking

Summary: this study will consist of 2 phases. phase 1 will be a one day crossover study to see the effects of study product on a smoker's desire to smoke, measured by changes in scores on questionnaires given over time. phase 2 will be a two-week extension, in which subjects will self-administer the study product and visit the study site for assessment of desire to smoke and collection of samples for the evaluation of smoking-related biomarkers.


Eligibility criteria:
inclusion criteria: * healthy adult smokers * using at least 1 pack of cigarettes per day, for at least 5 years exclusion criteria: * allergy to study product components

Keywords: dietary supplement nutraceutical
alterations in postprandial glucose and lipid metabolism in patients with obstructive sleep apnea

Conditions: Obstructive Sleep Apnea

Summary: the purpose of this study is to examine postprandial glucose and lipid metabolism in patients with obstructive sleep apnea.

obstructive sleep apnea (osa) is an increasingly prevalent condition that is characterized by repetitive upper airway obstructions. osa has been independently associated with insulin resistance, suggesting that osa may contribute to the development of type 2 diabetes and the metabolic syndrome. recently, postprandial glucose and lipid have been reported as excellent predictors for mortality and cardiovascular risk. however, the association between postprandial glucose, lipid metabolism and osa are not clear. in addition, humoral factors such as ghrelin and leptin are associated with obesity and osa, but postprandial changes of which in patients with osa are not well known. the aim of present study is to examine postprandial glucose and lipid metabolism, humoral factors in osa before and after 3 months of continuous positive airway pressure (cpap) treatment.

Eligibility criteria:
inclusion criteria: * subjects on admission for sleep study under the respiratory care and sleep control medicine, kyoto university hospital. * subjects diagnosed with osa (apnea hypopnea index \>=5/hour) by overnight polysomnography. exclusion criteria: * subjects treating for acute infections or malignancy. * subjects with severe anemia, diabetes,and renal failure.

Keywords: postprandial glucose, lipid metabolism humoral factors
transcranial magnetic stimulation in treatment of attention deficit/hyperactivity disorders

Conditions: Attention Deficit/Hyperactivity Disorder

Summary: * adhd is one of the most common psychiatric disorders. * while most of the attention is directed towards youth, 60% continue to suffer symptoms into adult life. * current treatment is effective, but 30% suffer side effects that lowers qol, and 20% are non-responders. * known mechanism of pathophysiology includes hypoactive dopaminergic system, especially at right pfc. * it is this study hypothesis that by stimulating the right pfc by tms, it will be possible to alleviate adhd symptoms. * a 10 sessions of treatment will by applied on a randomly allocated group of patients, diagnosed with adhd, in a 2:1 ratio: the first group will receive an actual tms treatment, and the second group will receive a sham treatment. * improvement of objective and subjective adhd scale will be examined.


Eligibility criteria:
inclusion criteria: * age 18-50 * established diagnosis of adhd * no c/i for tms * has signed an informed consent form exclusion criteria: * major psychiatric disorders (psychotic or affective) * active use of drugs (4 weeks prior to participation) * neurologic disorder such as epilepsy. * no use of stimulants during the previous 7 days

Keywords: adhd attention deficit/hyperactivity disorder tms transcranial magnetic stimulation
sphenopalatine ganglion block with tx360 for trigeminal neuralgia

Conditions: Trigeminal Neuralgia

Summary: the aim of this study was to investigate the effect of sphenopalatine ganglion (spg) block bilaterally through a nasal device called tx360 by delivering 0.3cc of lidocaine 2% for pain relief in patients with trigeminal neuralgia (tn).

trigeminal neuralgia (tn) is a chronic condition that causes sudden, intense facial pain that has a severe impact on patients' life quality and everyday functioning. even with many treatments available, some patients still struggle to manage their pain effectively. sphenopalatine ganglion (spg) block, delivered through a recently introduced nasal applicator called tx360, has shown promising results for those patients suffering persistent facial pain, icluding cases of tn. the purpose of this study was to observe how effective the spg block delivering lidocaine 2% via the tx360 is for pain relief in patients with tn. the patients' diagnosis included classical or atypical tn affecting the v2 (maxillary) or v3 (mandibular) branches, with partial or complete resistance to medication. researchers measured pain levels using the numerical rating scale (nrs) and evaluated the effects of treatment on patients' physical and mental wellbeing using the short form-36 (sf-36) quality of life questionnaire.

Eligibility criteria:
inclusion criteria: * male or female * older than 18 years * asa i or ii * trigeminal neuralgia of any etiology exclusion criteria: * anatomical abnormalities of the nasal septum, * rhinitis or nasal inflammation due to medication, * nasal septum perforation, * nasal or paranasal sinus surgery (within the last 3 months) * dryness or irritation of the nasal mucosa, localized pain, nasal discharge, or bleeding from the nose, * disorders related to bleeding or coagulation, * significant respiratory distress, * presence of malignancies, including angiofibroma or other tumors of the paranasal sinuses, or granulomas, * persistent nasal congestion lasting more than 10 days, accompanied by high fever, discolored nasal mucosa, or facial pain and headaches, * nasal or skull fractures occurring within the last 3 months

Keywords: trigeminal neuralgia spg block tx360 nasal applicator
quelimmune (scd-ped) pediatric surveillance registry

Conditions: Acute Kidney Injury; Acute Kidney Injury Due to Sepsis

Summary: quelimmune is fda-approved under an hde for the treatment of pediatric patients (weight ≥10kg and age ≤22 years) with aki due to sepsis or a septic condition on antibiotic therapy and requiring rrt. the purpose of this surveillance registry is to prospectively collect safety data among all patients treated with quelimmune under the hde. more specifically, we intend on comparing the incidence of new (secondary) blood stream infections in the first 28 days after scd-ped initiation to a comparator group of matched ckrt patients with sepsis who did not receive treatment with quelimmune


Eligibility criteria:
inclusion criteria: * all patients initiated on quelimmune therapy under the hde-approved indication exclusion criteria: * weight \<10kg * age \>22 years * known allergy to any components of quelimmune

Keywords: continuous kidney replacement therapy continuous renal replacement therapy acute kidney injury organ failure inflammation dialysis
epidemiology and acute oral effects electronic cigarette

Conditions: Nicotine Dependence, Cigarettes

Summary: electronic cigarettes are battery-powered vaporizers which have a similar feel to tobacco smoking. they do not produce cigarette smoke but rather an aerosol, which is frequently referred to as vapor. e-cigarettes are marketed as less harmful alternatives to smoking. use and awareness of these devices has grown exponentially in recent years, with millions of people currently using them. the benefits and risks of electronic cigarette use are uncertain. there is no research on the acute oral effects of electronic cigarette in the scientific literature and no hungarian epidemiological survey has been performed in this topic. regulation of electronic cigarettes varies across countries in the european union, ranging from no regulation to banning them entirely. the investigators research could help to integrate the regulation of this device in hungary and in the eu as well. the measurement of acute oral effects of e-cigarette and a hungarian epidemiological survey would be novel in this topic.

the epidemiological survey is performed with online questionnaires, which are published on e-cigarette-selling websites and on other forums dealing with this topic. the main outcome of interest was whether or not e-cigarette use helped people to quit smoking or reduce the number of conventional cigarettes. participants were also asked about the reason for starting e-cigarette use. nationality, habitation, citizenship status were included as demographic predictors in analyses. measurements of acute oral effects before and after using electronic cigarette with nicotine, without nicotine, conventional cigarette and placebo device: * measurement of exhaled co changes by smokerlyzer pico * measurement of saliva mmp-8 by periosafe home * measurement of saliva ph, buffering capacity, and flow rate changes by saliva check buffer kit (gc) * measurement of oral mucosal blood flow changes by perilam psi system high resolution (lasca method)

Eligibility criteria:
inclusion criteria: * age: 19-49 years * signed consent form * smoking regularly e-cigarette and/or conventional cigarette for \> half year exclusion criteria: * not pregnant and not planning pregnancy in the next 6 month * bmi index \< 30 * no severe parodontal disease * no acute illness in the last 2 weeks * no chronic disease (eg.: diabetes) * no diet which can influence the oral ph

Keywords: e-cigarette blood flow oral effects oral ph